Researchers at UC Berkeley report that an experimental compound called TOFA helped obese mice burn fat while preserving muscle, raising energy expenditure by up to 18% without added exercise.
The findings, published in Science Advances, point toward a new route for treating obesity, diabetes, and fatty liver disease — but no human benefit has yet been shown.
Why it matters now: the most prescribed obesity drugs, the GLP-1 class that includes Ozempic and Wegovy, work by cutting appetite. That approach delivers substantial weight loss, but it can also leave patients eating too little and losing muscle — tissue that matters for strength, mobility, and long-term metabolic health. The Berkeley team went after the other lever.
“Body weight responds to two levers: taking in fewer calories, or spending more energy. GLP-1s work almost entirely on the first, so we went after the second,” explained Anders Näär, a UC Berkeley professor of metabolic biology and nutrition who led the study as its senior author.
Experimental compound burns fat while sparing muscle in mice
- Current weight-loss drugs like Ozempic mainly make you eat less; this experimental compound, in mice, made the body burn more energy instead.
- In the animal studies, weight came off as fat while muscle was largely spared — the key drawback researchers are trying to solve with today’s medications.
- Nothing here is available to patients yet: the compound has not been tested in people, and its safety and effectiveness in humans remain unknown.
What TOFA does differently
The compound, 5-tetradecyloxy-2-furoic acid, or TOFA, was originally discovered in the 1970s. The new research uncovered properties the earlier work missed.
TOFA belongs to a class called ACC inhibitors — substances that block enzymes the body uses to manufacture fatty acids, slowing the production of certain fats. While other ACC inhibitors have reached mid-stage clinical trials in the past, no drug from this class has ever gained approval for treating a metabolic disease. A recurring obstacle: many of them increase triglycerides in the blood, potentially raising the risk of heart problems.

TOFA does something extra. The compound also switches on two cellular receptors, PPARα and PPARδ, which play a role in controlling the genes that govern fat metabolism.
Once switched on, these receptors set in motion processes by which cells take up fatty acids and break them down to generate energy. The net effect is that TOFA at once curbs the making of certain fats while spurring the body to burn the fat it already has.
That dual mechanism showed up in the results. Treated mice became more sensitive to insulin — the hormone that helps move glucose from the bloodstream into cells — and their triglyceride levels fell. Markers of fatty liver disease, in which fat accumulates inside liver cells, also improved. Weight loss came mainly from losing body fat, without losing much lean muscle.
The 18% rise in energy expenditure occurred without requiring additional physical activity and without raising body temperature.
“In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement,” Näär said.
Where TOFA fits with Ozempic
In their experiments, the researchers paired TOFA with semaglutide — the active ingredient in both Ozempic and Wegovy — and also with tirzepatide, sold under the brand names Mounjaro and Zepbound. In mice, the results were more favorable than those produced by either treatment alone.
The contrast between the two approaches is the core of the story:
| Approach | Primary mechanism | Muscle effect (mice) | Triglyceride effect |
|---|---|---|---|
| GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) | Reduce appetite and food intake | Risk of muscle loss with inadequate nutrition | Not the target of the study’s comparison |
| TOFA alone | Increases energy expenditure up to 18%; blocks fat production | Fat lost, lean mass largely preserved | Lowered |
| TOFA plus GLP-1 (mice) | Intake reduction plus energy burn | Greater metabolic improvement than either alone | Improved |
Earlier ACC inhibitors raise a caution worth stating plainly: their tendency to push triglycerides up is why none has reached approval for metabolic disease. TOFA did not raise triglycerides in these mouse experiments, which the researchers attribute to its additional receptor activity — but that pattern is an animal result, not a human safety profile.
Who funds it, and what comes next
Funding for the work came from discretionary resources at UC Berkeley, supplemented by support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. The Berkeley scientists have formed a biotechnology company, ReRx Therapeutics, to move the work toward clinical use, with backing from the university’s life sciences entrepreneurship network, including Nucleate and Berkeley SkyDeck.
Regulatory context matters for patients watching this space. No such application exists yet. Other ACC inhibitors have advanced to mid-stage trials before and stalled — a reminder that mouse metabolism does not reliably predict human outcomes.
Consult clinician before changing GLP-1 treatment
According to the source reporting, the compound's effectiveness and safety have not been established in humans, so no contraindication list yet exists.
Anyone on a GLP-1 medication experiencing nausea, digestive problems, signs of inadequate nutrition, or muscle weakness should consult their prescribing clinician rather than change or stop treatment on their own.
The open question
Everything published so far comes from mouse studies. Whether TOFA can deliver the same metabolic improvements in people — burning fat, sparing muscle, complementing GLP-1 drugs — is precisely what has not been answered, and the researchers themselves say human trials are still needed before any clinical claim can be made.
The study comes from UC Berkeley, a public research university founded in 1868 and the founding campus of the University of California system.
Its researchers have long shaped metabolic and biomedical science: the campus is home to Lawrence Berkeley National Laboratory, originally established as part of the university, and counts 65 Nobel laureates among its alumni, faculty, and researchers. Today the university enrolls more than 45,000 students, and federal funding for its research and development exceeded $1 billion in 2021.
References
- Lee, J.Y., Näär, A., et al. — TOFA study, Science Advances (UC Berkeley).
Consult a qualified healthcare professional before making decisions about any medication or treatment.
Worth a look
- Study: Bariatric Surgery, Switching GLP-1s Beat Stopping Treatment for Weight Loss
- RMIT-Invented Waterproof Wireless ECG Patch Enters Clinical Trial
- Thanksgiving Dinner Costs Rise 6% This Year, Farm Bureau Survey Finds (archynewsy.com)
- University of Canterbury Study Finds ChatGPT Translates Mental Health Tools Inconsistently (news-usa.today)